| Literature DB >> 33879468 |
Janneau L J Claessens1, Daniel A Godefrooij2, Gerko Vink3, Laurence E Frank3, Robert P L Wisse2.
Abstract
BACKGROUND: The aetiology of keratoconus (KC) remains poorly understood. KC has typically been described as a non-inflammatory disorder of the cornea. Nonetheless, there is increasing presumptive evidence for the role of the immune system in the pathogenesis of KC. AIM: To evaluate the association between KC and immune-mediated diseases on a population level. We hypothesise that KC is immune-mediated rather than a predominantly degenerative disease.Entities:
Keywords: cornea; epidemiology; immunology; inflammation
Mesh:
Year: 2021 PMID: 33879468 PMCID: PMC9510397 DOI: 10.1136/bjophthalmol-2021-318804
Source DB: PubMed Journal: Br J Ophthalmol ISSN: 0007-1161 Impact factor: 5.908
Characteristics of keratoconus patients and age-matched/sex-matched control group of the Achmea Health Database
| Characteristics | Keratoconus cases | Controls | Total |
| No. of enrollees (%) | 2051 (14.3) | 12 306 (85.7) | 14 357 |
| Years of enrolment in plan, no. (%) | |||
| 1 year | 45 (2.2) | 973 (7.9) | 1018 (7.1) |
| 2 years | 101 (4.9) | 956 (7.8) | 1057 (7.4) |
| 3 years | 183 (8.9) | 1217 (9.9) | 1400 (9.8) |
| 4 years | 218 (10.6) | 1304 (10.6) | 1522 (10.6) |
| 5 years | 205 (10.0) | 1146 (9.3) | 1351 (9.4) |
| 6 years | 1299 (63.3) | 6710 (54.5) | 8009 (55.8) |
| Age in years, mean (SD) | 29.7 (6.5) | 29.8 (6.4) | 29.8 (6.5) |
| Sex, no. (%) | |||
| Male | 1289 (62.8) | 7734 (62.8) | 9023 (62.8) |
| Female | 762 (37.2) | 4572 (37.2) | 5534 (37.2) |
| Socioeconomic status, no. (%) | |||
| Below average | 688 (33.5) | 3227 (26.2) | 3915 (27.3) |
| Average | 1038 (50.6) | 6824 (55.5) | 7863 (54.8) |
| Above average | 277 (13.5) | 1708 (13.9) | 1985 (13.8) |
| Unknown | 48 (2.3) | 1546 (4.4) | 594 (4.1) |
| Urbanisation status, no. (%) | |||
| Urban | 1635 (79.7) | 8790 (71.4) | 10 425 (72.6) |
| Rural | 378 (18.4) | 3050 (24.8) | 3428 (23.9) |
| Unknown | 38 (1.9) | 466 (3.8) | 504 (3.5) |
Data are no. (%) or mean (SD).
Socioeconomic status and urbanisation status are based on ‘postal codes’-related data from the Statistics Netherlands.14 Socioeconomic status is determined by a neighbourhood’s average income, level of unemployment, percentage of low-income households, and percentage of people with a low level of education. Urban and rural areas are defined as ≥1000 and <1000 households per km2, respectively.
Frequencies and conditional logistic regression model estimating associations of diseases with keratoconus compared with matched controls of the Achmea Health Database
| OR (95% CI) | P values | Keratoconus cases, no. (%) | Controls, no. (%) | |
|
| ||||
| Allergic rash |
|
| 5 (0.2) | 10 (0.1) |
| Hashimoto’s thyroiditis |
|
| 11 (0.5) | 23 (0.2) |
| Asthma/BHR |
|
| 30 (1.5) | 74 (0.6) |
| Allergic rhinitis |
|
| 8 (0.4) | 20 (0.2) |
| Rheumatoid Arthritis | 2.22 (0.71 to 6.97) | 0.173 | 4 (0.2) | 11 (0.1) |
| Inflammatory skin conditions* |
|
| 24 (1.2) | 66 (0.5) |
| Psoriasis and psoriatic arthritis | 1.60 (0.89 to 2.89) | 0.116 | 14 (0.7) | 53 (0.3) |
| Diabetes mellitus | 1.60 (0.85 to 3.03) | 0.149 | 12 (0.6) | 46 (0.4) |
| Ulcerative colitis | 1.46 (0.54 to 3.86) | 0.463 | 5 (0.2) | 21 (0.2) |
| Crohn’s Disease | 0.94 (0.33 to 2.70) | 0.942 | 4 (0.2) | 26 (0.2) |
| Graves’ disease | 0.92 (0.21 to 4.07) | 0.910 | 2 (0.1) | 13 (0.1) |
| Multiple sclerosis | 0.63 (0.15 to 2.72) | 0.538 | 2 (0.1) | 19 (0.2) |
| Ankylosing spondylitis | 0.59 (0.76 to 4.62) | 0.617 | 1 (0.0) | 10 (0.1) |
| Sarcoidosis | 0.42 (0.06 to 3.16) | 0.396 | 1 (0.0) | 15 (0.1) |
|
| ||||
| Obstructive sleep apnoea |
|
| 10 (0.5) | 26 (0.2) |
Univariate analysis with adjustment for age, sex, socioeconomic status and urbanisation status. An uncorrected analysis of disease associations did not materially differ from presented outcomes above (data not shown). Bold values represent statistically significant outcomes.
*Inflammatory skin conditions include contact dermatitis, hives/urticaria and other non-specified inflammatory dermatoses.
BHR, bronchial hyperresponsiveness; IMIDs, immune-mediated inflammatory diseases.